Iran to start receiving Covid-19 vaccines developed by AstraZeneca in Feb

Namaki also said that Iran's Razi Vaccine and Serum Research Institute has been authorized to start clinical trials of its vaccine candidate, and they will hopefully start the trials next week

AstraZeneca
So far, 9,449,685 tests for COVID-19 have been carried out in Iran, according to the spokesperson.
IANS Tehran
2 min read Last Updated : Feb 04 2021 | 12:31 PM IST

Iran will start receiving doses of the AstraZeneca vaccine in February via the Covid-19 Vaccines Global Access (COVAX) platform, Minister of Health and Medical Education Saeed Namaki announced.

"AstraZeneca informed us the night before last that it will start delivering 4.2 million doses in February within the framework of COVAX," Namaki said in a video announcement on Wednesday.

Namaki also said that Iran's Razi Vaccine and Serum Research Institute has been authorised to start clinical trials of its vaccine candidate, and they will hopefully start the trials next week.

At her daily briefing, spokeswoman for the ministry, Sima Sadat Lari, said 6,870 new Covid-19 cases were detected in the past 24 hours, raising the country's overall count to 1,438,286 infections.

Of the newly infected, she noted, 701 had to be hospitalised.

Between Tuesday and Wednesday, she added, 79 new deaths related to the coronavirus were registered, taking a death toll of 58,189 in the country.

She said 1,229,391 Covid-19 patients have as of Wednesday recovered or been released from Iranian hospitals.

So far, 9,449,685 tests for Covid-19 have been carried out in Iran, according to the spokesperson.

Iran announced its first Covid-19 cases on February 19, 2020.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :IranAstraZenecaCoronavirus Vaccine

First Published: Feb 04 2021 | 12:23 PM IST

Next Story